Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?

Annals of Surgical Oncology

Volumn 22, Issue 6, 2015, Pages 1858-1865

  Cools Lartigue, J ^a   Jones, D ^a   Spicer, J ^a   Zourikian, T ^a   Rousseau, M ^a   Eckert, E ^a   Alcindor, T ^a   Vanhuyse, M ^a   Asselah, J ^a   Ferri, L E ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM COMPLEX; TAXOID;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; ADVERSE EFFECTS; AGED; CANCER STAGING; CHEMICALLY INDUCED; COMPLICATION; DEGLUTITION DISORDERS; DRUG EFFECTS; ENTERIC FEEDING; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEGLUTITION DISORDERS; ENTERAL NUTRITION; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TAXOIDS;

EID: 84939962321     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-4270-9     Document Type: Article

References (45)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and ngastric cardia. JAMA. 1991;265:1287–9.
2. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.
3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
4. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.
5. Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012;23:1512–7.
6. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
7. Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol. 2002;28:396–400.
8. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.
9. Eldeeb H, El-Hadaad HA. Radiotherapy versus stenting in treating malignant dysphagia. J Gastrointest Oncol. 2012;3:322–5.
10. Kujawski K, Stasiak M, Rysz J. The evaluation of esophageal stenting complications in palliative treatment of dysphagia related to esophageal cancer. Med Sci Monitor. 2012;18:CR323–9.
11. Lopes TL, Eloubeidi MA. A pilot study of fully covered self-expandable metal stents prior to neoadjuvant therapy for locally advanced esophageal cancer. Dis Esophagus. 2010;23:309–15.
12. Pellen MG, Sabri S, Razack A, Gilani SQ, Jain PK. Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. Dis Esophagus. 2012;25:48–53.
13. Llaguna OH, Kim HJ, Deal AM, Calvo BF, Stitzenberg KB, Meyers MO. Utilization and morbidity associated with placement of a feeding jejunostomy at the time of gastroesophageal resection. J Gastrointest Surg. 2011 Oct;15:1663–9.
14. Adler DG, Fang J, Wong R, Wills J, Hilden K. Placement of Polyflex stents in patients with locally advanced esophageal cancer is safe and improves dysphagia during neoadjuvant therapy. Gastrointest Endosc. 2009;70:614–9.
15. Schrag SP, Sharma R, Jaik NP, Seamon MJ, Lukaszczyk JJ, Martin ND, et al. Complications related to percutaneous endoscopic gastrostomy (PEG) tubes. A comprehensive clinical review. J Gastrointest Liver Dis. 2007;16:407–18.
16. Hilal RE, Hilal T, Mushawahar A. Percutaneous endoscopic jejunostomy feeding tube “knot” working: a rare complication. Clin Gastroenterol Hepatol. 2007;5:A28.
17. Maple JT, Petersen BT, Baron TH, Gostout CJ, Wong Kee Song LM, Buttar NS. Direct percutaneous endoscopic jejunostomy: outcomes in 307 consecutive attempts. Am J Gastroenterol. 2005;100:2681–8.
18. Sonawane RN, Thombare MM, Kumar A, Sikora SS, Saxena R, Kapoor VK, et al. Technical complications of feeding jejunostomy: a critical analysis. Trop Gastroenterol. 1997;18:127–8.
19. Chong AK, Delegge MH. Necrotizing fasciitis after direct percutaneous endoscopic jejunostomy. Gastrointest Endosc. 2005;61:912–3.
20. Ishii M, Teramoto S, Yakabe M, Yamamato H, Yamaguchi Y, Hanaoka Y, et al. Small intestinal intussusceptions caused by percutaneous endoscopic jejunostomy tube placement. J Am Geriatr Soc. 2007;55:2093–4.
21. Sica GS, Sujendran V, Wheeler J, Soin B, Maynard N. Needle catheter jejunostomy at esophagectomy for cancer. J Surg Oncol. 2005;91:276–9.
22. Mackenzie SH, Haslem D, Hilden K, Thomas KL, Fang JC. Success rate of direct percutaneous endoscopic jejunostomy in patients who are obese. Gastrointest Endosc. 2008;67:265–9.
23. Margolis M, Alexander P, Trachiotis GD, Gharagozloo F, Lipman T. Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer. Ann Thorac Surg. 2003;76:1694–7.
24. Rumalla A, Baron TH. Results of direct percutaneous endoscopic jejunostomy, an alternative method for providing jejunal feeding. Mayo Clin Proc. 2000;75:807–10.
25. Ohnmacht GA, Allen MS, Cassivi SD, Deschamps C, Nichols FC 3rd, Pairolero PC. Percutaneous endoscopic gastrostomy risks rendering the gastric conduit unusable for esophagectomy. Dis Esophagus. 2006;19:311–2.
26. Siddiqui AA, Sarkar A, Beltz S, Lewis J, Loren D, Kowalski T, et al. Placement of fully covered self-expandable metal stents in patients with locally advanced esophageal cancer before neoadjuvant therapy. Gastrointest Endosc. 2012;76:44–51.
27. Rao C, Haycock A, Zacharakis E, Krasopoulos G, Yakoub D, Protopapas A, et al. Economic analysis of esophageal stenting for management of malignant dysphagia. Dis Esophagus. 2009;22:337–47.
28. Sreedharan A, Harris K, Crellin A, Forman D, Everett SM. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2009;(4):CD005048.
29. Siddiqui AA, Loren D, Dudnick R, Kowalski T. Expandable polyester silicon-covered stent for malignant esophageal strictures before neoadjuvant chemoradiation: a pilot study. Dig Dis Sci. 2007;52:823–9.
30. Ferreira F, Bastos P, Ribeiro A, Marques M, Azevedo F, Pereira P, et al. A comparative study between fluoroscopic and endoscopic guidance in palliative esophageal stent placement. Dis Esophagus. 2012;25:608–13.
31. Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol. 2012;18:6737–46.
32. Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer. 2006;107:854–63.
33. Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Hammerlid E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18:131–9.
34. Saito T, Kuwahara A, Shigemitsu Y, Kinoshita T, Shimoda K, Miyahara M, et al. Factors related to malnutrition in patients with esophageal cancer. Nutrition. 1991;7:117–21.
35. Bozzetti F, Cozzaglio L, Gavazzi C, Bidoli P, Bonfanti G, Montalto F, et al. Nutritional support in patients with cancer of the esophagus: impact on nutritional status, patient compliance to therapy, and survival. Tumori. 1998;84:681–6.
36. Ligthart-Melis GC, Weijs PJ, te Boveldt ND, Buskermolen S, Earthman CP, Verheul HM, et al. Dietician-delivered intensive nutritional support is associated with a decrease in severe postoperative complications after surgery in patients with esophageal cancer. Dis Esophagus. 2013;26:587–93.
37. Ryan AM, Rowley SP, Healy LA, Flood PM, Ravi N, Reynolds JV. Post-oesophagectomy early enteral nutrition via a needle catheter jejunostomy: 8-year experience at a specialist unit. Clin Nutr. 2006;25:386–93.
38. Ott C, Ratiu N, Endlicher E, Rath HC, Gelbmann CM, Scholmerich J, et al. Self-expanding Polyflex plastic stents in esophageal disease: various indications, complications, and outcomes. Surg Endosc. 2007;21:889–96.
39. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305–13.
40. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.
41. van Meerten E, van der Gaast A, Looman CW, Tilanus HW, Muller K, Essink-Bot ML. Quality of life during neoadjuvant treatment and after surgery for resectable esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2008;71:160–6.
42. Blazeby JM, Sanford E, Falk SJ, Alderson D, Donovan JL. Health-related quality of life during neoadjuvant treatment and surgery for localized esophageal carcinoma. Cancer. 2005;103:1791–9.
43. Safieddine N, Xu W, Quadri SM, Knox JJ, Hornby J, Sulman J, et al. Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention. J Thorac Cardiovasc Surg. 2009;137:36–42.
44. Becerra CR, Hanna N, McCollum AD, Becharm N, Timmerman RD, DiMaio M, et al. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92. J Thorac Oncol. 2013;8:1425–9.
45. Zanoni A, Verlato G, Giacopuzzi S, Weindelmayer J, Casella F, Pasini F, et al. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. Ann Surg Oncol. 2013;20:1993–9.